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ATYPICAL ANTIPSYCHOTIC DRUGS
Two points of clinical interest
Rajeev Krishnadas clinical lecturer in psychological medicine
University of Glasgow, Glasgow, UK
Two points of clinical interest add to Mackin and Thomas’s
summary of the indications for and use of atypical antipsychotic
drugs.1
Firstly, up to 5% of patients with schizophrenia commit suicide,2
which is similar to the rates in major depression and
considerably higher than those in the general population.
Suicidal ideation at initial presentation is thought to predict
suicide attempt in the near future.3 Clozapine is the only
antipsychotic drug with an anti-suicidal effect,4 so it may be
useful in clinically significant suicidal ideation, especially
secondary to psychotic symptoms.
Secondly, recent long term follow-up data suggest that
antipsychotic use may be an independent risk factor for
generalised and specific reduction in grey matter volume.5 This
effect was dose dependent, the changes were subtle, and atypical
antipsychotics were milder than typical antipsychotics.
Antipsychotic use must therefore be judicious and the minimal
effective dose tailored to each patient.
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